UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 575

Sortiert nach

Efficacy and safety of dolutegravir with emtricitabine and tenofovir alafenamide fumarate or tenofovir disoproxil fumarate, and efavirenz, emtricitabine, and tenofovir disoproxil fumarate HIV antiretroviral therapy regimens started in pregnancy (IMPAACT 2010/VESTED): a multicentre, open-label, randomised, controlled, phase 3 trial

The Lancet (British edition), 2021-04, Vol.397 (10281), p.1276-1292

2021

Link zum Volltext

Verfügbarkeit prüfen

Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3b study

The Lancet (British edition), 2014-06, Vol.383 (9936), p.2222-2231

2014

Link zum Volltext

Verfügbarkeit prüfen

Tenofovir alafenamide: A novel prodrug of tenofovir for the treatment of Human Immunodeficiency Virus

Antiviral research, 2016-01, Vol.125, p.63-70

2016

Link zum Volltext

Verfügbarkeit prüfen

Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial

The Lancet (British edition), 2011-07, Vol.378 (9787), p.238-246

2011

Link zum Volltext

Verfügbarkeit prüfen

Design, formulation and evaluation of novel dissolving microarray patches containing a long-acting rilpivirine nanosuspension

Journal of controlled release, 2018-12, Vol.292, p.119-129

2018

Link zum Volltext

Verfügbarkeit prüfen

HIV

The Lancet (British edition), 2018-08, Vol.392 (10148), p.685-697

2018

Link zum Volltext

Verfügbarkeit prüfen

Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3, randomised, non-inferiority trial

The Lancet (British edition), 2011-07, Vol.378 (9787), p.229-237

2011

Link zum Volltext

Verfügbarkeit prüfen

Creation of a nanoformulated cabotegravir prodrug with improved antiretroviral profiles

Biomaterials, 2018-01, Vol.151, p.53-65

2018

Link zum Volltext

Verfügbarkeit prüfen

Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3, non-inferiority trial

The Lancet (British edition), 2012-06, Vol.379 (9835), p.2429-2438

2012

Link zum Volltext

Verfügbarkeit prüfen

Long-term data on the efficacy and tolerability of lamivudine plus dolutegravir as a switch strategy in a multi-centre cohort of HIV-1-infected, virologically suppressed patients

International journal of antimicrobial agents, 2019-12, Vol.54 (6), p.728-734

2019

Link zum Volltext

Verfügbarkeit prüfen

Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks

The Lancet (British edition), 2012-06, Vol.379 (9835), p.2439-2448

2012

Link zum Volltext

Verfügbarkeit prüfen

Mechanism of transport of saquinavir-loaded nanostructured lipid carriers across the intestinal barrier

Journal of controlled release, 2013-03, Vol.166 (2), p.115-123

2013

Link zum Volltext

Verfügbarkeit prüfen

Drug concentrations after topical and oral antiretroviral pre-exposure prophylaxis: implications for HIV prevention in women

The Lancet (British edition), 2011-07, Vol.378 (9787), p.279-281

2011

Link zum Volltext

Verfügbarkeit prüfen

Nanoparticles-in-film for the combined vaginal delivery of anti-HIV microbicide drugs

Journal of controlled release, 2016-12, Vol.243, p.43-53

2016

Link zum Volltext

Verfügbarkeit prüfen

Polymer-based nanocarriers for vaginal drug delivery

Advanced drug delivery reviews, 2015-09, Vol.92 (C), p.53-70

2015

Link zum Volltext

Verfügbarkeit prüfen

Electrospun cellulose acetate phthalate fibers for semen induced anti-HIV vaginal drug delivery

Biomaterials, 2012-01, Vol.33 (3), p.962-969

2012

Link zum Volltext

Verfügbarkeit prüfen

3D printed capsules for quantitative regional absorption studies in the GI tract

International journal of pharmaceutics, 2018-10, Vol.550 (1-2), p.418-428

2018

Link zum Volltext

Verfügbarkeit prüfen

Treatment of medical, psychiatric, and substance-use comorbidities in people infected with HIV who use drugs

The Lancet (British edition), 2010-07, Vol.376 (9738), p.367-387

2010

Link zum Volltext

Verfügbarkeit prüfen

Vaginal rings with exposed cores for sustained delivery of the HIV CCR5 inhibitor 5P12-RANTES

Journal of controlled release, 2019-03, Vol.298, p.1-11

2019

Link zum Volltext

Verfügbarkeit prüfen

Challenges in oral drug delivery of antiretrovirals and the innovative strategies to overcome them

Advanced drug delivery reviews, 2016-08, Vol.103, p.105-120

2016

Link zum Volltext

Verfügbarkeit prüfen

Degradable bioadhesive nanoparticles for prolonged intravaginal delivery and retention of elvitegravir

Biomaterials, 2017-11, Vol.144, p.144-154

2017

Link zum Volltext

Verfügbarkeit prüfen

Development of mucoadhesive vaginal films based on HPMC and zein as novel formulations to prevent sexual transmission of HIV

International journal of pharmaceutics, 2019-10, Vol.570, p.118643-118643, Article 118643

2019

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 575

Suche als RSS-Feed

Aktive Filter

KollektionElsevier Journal Backfiles on ScienceDirect (DFG Nationallizenzen)

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(543)
Mit Volltextzugriff
(574)

Publikationsform

Artikel
(575)

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(516)
Life Sciences & Biomedicine
(508)
Anti-Hiv Agents - Administration & Dosage
(505)
Humans
(503)
Female
(298)
Hiv Infections - Drug Therapy
(285)
Male
(241)
Hiv
(219)
Human Immunodeficiency Virus
(213)
Biological And Medical Sciences
(209)
Medical Sciences
(205)
Anti-Hiv Agents - Therapeutic Use
(192)
Adult
(179)
Pharmacology & Pharmacy
(167)
Infectious Diseases
(142)
Pharmacology. Drug Treatments
(129)
Animals
(127)
Hiv Infections - Prevention & Control
(120)
General & Internal Medicine
(115)
Medicine, General & Internal
(115)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 48-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study

Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3b study

Tenofovir alafenamide: A novel prodrug of tenofovir for the treatment of Human Immunodeficiency Virus

Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial

Design, formulation and evaluation of novel dissolving microarray patches containing a long-acting rilpivirine nanosuspension

HIV

Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3, randomised, non-inferiority trial

Creation of a nanoformulated cabotegravir prodrug with improved antiretroviral profiles

Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3, non-inferiority trial

Long-term data on the efficacy and tolerability of lamivudine plus dolutegravir as a switch strategy in a multi-centre cohort of HIV-1-infected, virologically suppressed patients

Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks

Mechanism of transport of saquinavir-loaded nanostructured lipid carriers across the intestinal barrier

Drug concentrations after topical and oral antiretroviral pre-exposure prophylaxis: implications for HIV prevention in women

Nanoparticles-in-film for the combined vaginal delivery of anti-HIV microbicide drugs

Polymer-based nanocarriers for vaginal drug delivery

Electrospun cellulose acetate phthalate fibers for semen induced anti-HIV vaginal drug delivery

Early time-limited antiretroviral therapy versus deferred therapy in South African infants infected with HIV: results from the children with HIV early antiretroviral (CHER) randomised trial

Bone mineral density and inflammatory and bone biomarkers after darunavir–ritonavir combined with either raltegravir or tenofovir–emtricitabine in antiretroviral-naive adults with HIV-1: a substudy of the NEAT001/ANRS143 randomised trial

3D printed capsules for quantitative regional absorption studies in the GI tract

Treatment of medical, psychiatric, and substance-use comorbidities in people infected with HIV who use drugs

Vaginal rings with exposed cores for sustained delivery of the HIV CCR5 inhibitor 5P12-RANTES

Challenges in oral drug delivery of antiretrovirals and the innovative strategies to overcome them

Degradable bioadhesive nanoparticles for prolonged intravaginal delivery and retention of elvitegravir

Development of mucoadhesive vaginal films based on HPMC and zein as novel formulations to prevent sexual transmission of HIV

Aktive Filter

Suchergebnisse filtern